Splenectomy for thrombocytopenia due to secondary hypersplenism.
The response to splenectomy of patients with thrombocytopenia due to secondary hypersplenism is frequently unpredictable. Our experience indicated that splenectomy is seldom justified for this indication in patients with chronic myelogenous or chronic granulocytic leukemia. Since patients with chronic lymphocytic leukemia, hairy-cell leukemia, and stage IV lymphoma may have a more prolonged life expectancy, removal of the spleen brings about a satisfactory response of thrombocytopenia in some instances. Elevation of platelet counts after splenectomy in patients with agnogenic myeloid metaplasia is most likely to occur in women with the primary form of the disease. In other nonmalignant conditions, splenectomy has resulted in a satisfactory response in the majority of patients.
Coon
W W
WW
Department of Surgery, University of Michigan Medical Center, Ann Arbor.
D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D006971:Hypersplenism / Q000150:complications / Q000209:etiology / Q000601:surgery*; D007943:Leukemia, Hairy Cell / Q000150:complications / Q000628:therapy; D007951:Leukemia, Myeloid / Q000150:complications / Q000628:therapy; D008223:Lymphoma / Q000150:complications / Q000628:therapy; D008297:Male; D055728:Primary Myelofibrosis / Q000150:complications / Q000628:therapy; D013156:Splenectomy; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy*